Novo Nordisk Rebrands as ‘Novo’ in Obesity Market Reset

Novo described the rebrand as the beginning of a new chapter, introducing the broader message “Lasting Health Starts Now.” The campaign is designed to strengthen the company’s relevance and trust among patients and other stakeholders while bringing its scientific developments closer to everyday health needs. Novo Nordisk will remain the company’s official legal name.

The shift comes during a challenging period for the drugmaker. Novo shares have fallen about 15% this year as investors weigh intensifying competition and questions about the company’s next generation of blockbuster medicines. Novo also recently discontinued three trials involving an experimental cardiovascular drug.

Competition with Eli Lilly remains one of the biggest challenges. According to IQVIA data cited in a Lilly earnings presentation, Novo held 38.8% of the obesity drug market in the second quarter, compared with Lilly’s 60.9%. The widening gap has increased pressure on Novo to strengthen its product portfolio and establish a clearer path toward long-term growth.

One bright spot has been the launch of oral Wegovy. The weight-loss pill surpassed 3 million prescriptions as of June and entered the market ahead of Lilly’s competing weight-loss pill, Foundayo. Its early momentum could give Novo an important platform as competition increasingly expands beyond injectable obesity treatments.

Alongside its commercial strategy, Novo is introducing four principles intended to reshape how the company operates. These include putting patients at the center of innovation, improving performance to create greater stakeholder value, simplifying priorities and workflows, and maintaining strict standards around patient safety and ethics.

The rebrand therefore represents more than a change in corporate identity. Novo is attempting to reposition itself for a more competitive phase of the obesity drug market, where product innovation, execution and direct relationships with consumers are becoming increasingly important. Investors will get a clearer view of how the company plans to translate these changes into growth when Novo presents its updated strategy on Sept. 21.